# Companion Diagnostic Market

> Companion Diagnostics Market Research Report Information by Test Type (HER2 Testing, PD-1 Testing, EGFR Mutation Testing, ALK Rearrangement Testing, and Others), By Product & Services (assays, reagents & kits, instruments/systems, and software & services), By Technology (polymerase chain reaction (PCR), next-generation sequencing (NGS), immunohistochemistry (IHC), Fluorescence In-Situ Hybridization (FISH), and others),By Indication (cancer, neurological disorders, cardiovascular disorders, and infectious diseases), By End User (Biopharmaceutical and Biotechnology Companies, CROs and CDMOs, and Others) By Region (North America, Europe, Asia-Pacific) - Forecast to 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 12.68%
- **2024:** $ 6,828.25 Million
- **2025:** $ 7,694.07 Million
- **2035:** $ 25,300.58 Million
- **Key Players:** Companies such as Qiagen, Bio-Techne, BioMérieux, Thermo Fisher Scientific Inc., Illumina, Inc., Agilent Technologies, Inc., F. Hoffmann-la Roche Ltd. are some of the major participants in the global market.

**Report ID:** MRFR/MED/2231-CR · **Pages:** 168 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** June 26, 2026

**URL:** https://www.marketresearchfuture.com/reports/companion-diagnostic-market-3077

---

## Market Summary

## **Global Companion Diagnostics Market Overview**

The Companion Diagnostics Market Size was valued at USD 23.97 billion in 2022 and is projected to grow from USD 29.70 Billion in 2023 to USD 161.95 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 23.90% during the forecast period (2023 - 2032).

The benefits of companion diagnostics drive the growth of the global companion diagnostics industry; the expanding need for targeted therapy, the importance of personalized medicine, the rising incidence of cancer worldwide, and the ever-expanding companion diagnostics application areas are the key market drivers enhancing the market growth. 

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

Labcorp received FDA approval for a companion diagnostic in April 2024 that is designed to be used along with Pfizer’s newly approved gene therapy for Hemophilia B patients.

Tempus said the FDA granted its HLA-LOH assay status as a CDx test with breakthrough device designation on August 2023. The analysis will rely on machine learning models for sequence data.

Agilent Technologies, Inc., based in the USA, secured European IVDR certification for its companion diagnostic assay in August 2023. QIAGEN (Netherlands) also got FDA approval for its companion diagnostics on July 16th, this time for Blueprint Medicines’ AYVAKIT (avapritinib) aimed at GIST or KIT-mutated GIST.

Allarity Therapeutics and DRP® Companion Diagnostics have signed an agreement with FivepHusion to support the clinical development of Deflexifol™, which treats solid tumors.

Tempus has announced a partnership with TScan Therapeutics in July 2023 to create a companion diagnostic (CDx) test for cancer patients.

F. Hoffmann-La Roche Ltd., Switzerland, got FDA approval for an extended label claim of VENTANA PD-L1 (SP263) assay on March 21st, targeting Libtayo eligible NSCLC patients.

PATHWAY, a companion diagnostic by F. Hoffmann-La Roche Ltd., was given the go-ahead in October 2022 to identify patients who qualify under HER2 metastatic breast cancer treatment ENHERTU (an anti-drug conjugate targeted against HER2).

HMNC Brain Health raised US$14.2 million in a funding round in October 2022 to support precision psychiatry programs that combine pharmaceuticals and companion diagnostics capable of identifying patient groups benefiting from such treatments.

OmniSeq Corporation debuted OmniSeq INSTsm in June 2022; this tissue-based test features next-generation sequencing (NGS) technology and aims to enhance precision oncology and patient outcomes.

Illumina Inc. teamed up with Soma Logic Operating Co. Inc. in January 2022 to introduce an assay for proteomics called Soma Scan into Illumina’s high-throughput next-generation sequencing platforms.

Denovo Biopharma LLC partnered with QIAGEN in December 2021 to develop a blood-based companion diagnostic (CDx) test that can identify patients expressing Denovo Genomic Marker 1(DGM1) who may respond to Denovo’s investigational drug DV102, a treatment for lymphoid tumors such as diffuse large B-cell lymphoma.

Qiagen N.V. (Germany) extended the Thera screen KRAS Kit in May 2021.

For instance, the Centers for Medicare and Medicaid Services (CMS), in January 2020, added cutting-edge sequence testing as an asymptotic tool used on germline (acquired) breast cancers.

## **Companion Diagnostics Market Trends**

### **Rising preference for personalized medicine market growth**

Personalized or targeted medicine is one of the upcoming trends in medical innovation. It is one of the most significant fields that creates the need for companion diagnostics products. The healthcare providers are focusing on using CDx to develop new drugs based on specific genetic biomarkers in major fields such as oncology, cardiac disease, inflammation, infectious diseases, central nervous system disorders, and many more to improve patient outcomes.

Moreover, the companion diagnostic tests are currently used to help identify specific genetic/somatic mutations in patient samples that are specified for targeted therapies for many different types of cancers. For instance, in July 2021, QIAGEN N.V. (Germany) partnered with Sysmex (Japan) to develop and market cancer companion diagnostics (CDx), leveraging the latter’s Plasma-Safe-SeqS technology for next-generation sequencing (NGS); this partnership aims to develop drug treatments for cancer and boost quick clinical use of ultra-sensitive liquid biopsy clinical diagnostics.

## **Companion Diagnostics Market Segment Insights**

### **Companion Diagnostics Product & Service Insights**

The Market segments of Companion Diagnostics, based on product & service, includes assays, kits, & reagents and software & services. The assays, kits, & reagents segment accounted for the largest market share in 2021. Assays, kits, & reagents are required for generating many DNA molecules using primers and preparing libraries from the newly developed DNA molecules. The reagents & test kits unit vary with the number of reactions to be carried out. Camptosar (irinotecan) and Invader UGT1A1 are common examples of molecular assay used in IVD testing.

### **Companion Diagnostics Technology Insights**

The Companion Diagnostics Market data has been segmented, based on technology, by polymerase chain reaction (PCR), next-generation sequencing (NGS), in situ hybridization (ISH), immunohistochemistry (IHC), and others. Polymerase chain reaction (PCR) is a technique used to make multiple copies of a specific genetic material (DNA/RNA) quickly. Polymerase chain reaction (PCR) plays an important role in companion diagnostic tests. This technique helps in screening the suitable treatment for the patient according to its genetic makeup and also helps to reduce the chances of the adverse effects and improves medical outcomes.

Polymerase chain reaction (PCR) is the most commonly used technology for the development of companion diagnostics as it provides large quantitative data for analysis.

### **Companion Diagnostics Indication Insights**

The Market data of Companion Diagnostics has been segmented, based on indication, by cancer, neurological diseases, infectious diseases, cardiovascular diseases, and others. The cancer further segmented into lung cancer, breast cancer, colorectal cancer, gastric cancer, and melanoma. The rising prevalence of cancer has accelerated the demand for companion diagnostics products across the globe. Companies such as QIAGEN N.V. (Germany) and F. Hoffmann-La Roche Ltd (Switzerland) are offering various companion diagnostic tools and kits to screen cancer patients.

For instance, in May 2021, QIAGEN N.V. (Germany) launched the first US Food Drug and Administration (FDA)-approved tissue companion diagnostic kit to identify the KRAS G12C mutation in NSCLC tumors.

August 2021: QIAGEN N.V. (Germany) and OncXerna (US) entered into a global agreement to advance the development of the Xerna TME panel as a potential next generation sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab.

**Figure 2: Companion Diagnostics Market, by Indication, 2022 & 2032 (USD Billion)**

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

### **Companion Diagnostics End User Insights**

Based on end user, the market of Companion Diagnostics is segmented into pharmaceutical & biopharmaceutical companies, contract research organizations, laboratories, and others. Pharmaceutical and biotech companies held the largest market size in 2021. This large share can be attributed to the increased adoption of companion diagnostics in drug discovery & development by pharmaceuticals and biotechnology companies. For instance, in August 2020, F. Hoffmann-La Roche Ltd. (Switzerland) launched FoundationOne liquid CDx that has been approved by the FDA for pan-tumor liquid biopsy tests to diagnose the solid tumor.

October 2021: Agilent Technologies, Inc. (US) received FDA companion diagnostic approval for ki-67 ihc mib pharmdx in high-risk early breast cancer.

### **Companion Diagnostics Regional Insights**

By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World. North America companion diagnostics market accounted for the largest market share in 2021, The increasing number of healthcare organizations working on generated genomic databases to understand the human genome and growing research activities in this region using companion diagnosis kits are also driving the market growth.

Further, the major countries studied are: The US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

**Figure 3: COMPANION DIAGNOSTICS MARKET SHARE (%) BY REGION**

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

Europe companion diagnostics market accounts for the second-largest market share due to the growing preference for personalized medicine and increasing collaboration among companies, and increasing product approval by major players coupled with the various government initiatives to promote companion diagnostics are some of the prominent factors driving the growth of the market of companion diagnostics. Furthermore, the Germany market of companion diagnostics held the largest market share in 2021, and the France market of companion diagnostics was the fastest growing market in the Europe region.

The rapid growth of the Asia-Pacific regional market is due to the increasing prevalence of infectious diseases, rising of proteomics & genomics, the growing number of cancer patients, cardiovascular and neurological diseases, and growing research funding and rising investments by pharmaceutical biotechnological companies. According to the Alzheimer's Association report, countries such as India have more than four million people with some form of dementia and Alzheimer's, the most common type of dementia. Moreover, China market of companion diagnostics held the largest market share, and the India market of companion diagnostics was the fastest growing market in the Asia-Pacific region.

## **Companion Diagnostics Key Market Players & Competitive Insights**

Major market players are spending a lot of money on R&D to increase their product lines, which will help the market of companion diagnostics grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, including new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the companion diagnostics industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

In addition, Thermo Fisher Scientific, Inc. (US) specializes in various biotechnology products such as analytical instruments, laboratory supply chain programs and e-commerce, laboratory equipment, lab services, and specialty diagnostics. The company helps its customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to the market, and increase the productivity of the laboratory. In December 2021, the company received approval for Oncomine Dx Target Test as a companion diagnostic (CDx) by the FDA that aims to assist healthcare experts in identifying non-small cell lung cancer patients whose tumors carry epidermal growth factor receptor (EGFR).

Hoffmann-La Roche Ltd (Switzerland) is one of the leading companies in the field of diagnostics and pharmaceuticals. The company develops and markets products for diagnosis and treatment of anemia, cancer, anticoagulation therapy, cardiovascular diseases, diabetes, central nervous system, chlamydia, dermatology, gonorrhea, gout, hepatitis B and C, hemostasis disorders, HIV/AIDS, HPV, infectious diseases, and autoimmune diseases. In August 2020, the company announced the approval of FoundationOne liquid CDx by the FDA. The product is applicable for pan tumor liquid biopsy tests. This launch aims to strengthen the company’s companion diagnostics product portfolio.

### **Key Companies in the Companion Diagnostics Market include.**

- [Hoffmann-La Roche Ltd](https://www.roche.com/media/releases/med-cor-2022-10-04) (Switzerland)
- Thermo Fisher Scientific Inc. (US)
- Agilent Technologies, Inc. (US)
- QIAGEN N.V. (Germany)
- Abbott Laboratories, Inc. (US)
- BioMérieux SA (France)
- [Leica Biosystems Nussloch](https://www.leicabiosystems.com/en-in/ihc-ish/companion-diagnostics/) GmbH (Germany)
- Illumina, Inc. (US)
- Myriad Genetics, Inc. (US)
- ArcherDX, Inc. (US)
- Others

### **Companion Diagnostics Industry Developments**

December 2021: QIAGEN N.V. (Germany) partnered with Denovo Biopharma (US) to develop companion diagnostic tests for the treatment of diffuse large B-cell lymphoma.

October 2021: Agilent Technologies, Inc. (US) PD-L1 IHC 22C3 pharmadx assay got approval in the European Union for use in triple-negative breast cancer.

September 2021: Food Drug and Administration approved tissue based NGS companion diagnostics for Takeda's targeted therapy for NSCLC patients with EGFR Exon 20 insertion mutations.

## **Companion Diagnostics Market Segmentation**

### **Companion Diagnostics Product & Service Outlook**

- Assays, Kits, & Reagents
- Software & Services

### **Companion Diagnostics Application Outlook**

- Polymerase Chain Reaction (PCR)
- Next-Generation Sequencing (NGS)
- In Situ Hybridization (ISH)
- Immunohistochemistry (IHC)
- Others

### **Companion Diagnostics Indication Outlook**

### **Companion Diagnostics End User Outlook**

- Pharmaceutical & Biopharmaceutical Companies
- Contract Research Organizations
- Laboratories
- Others

### **Companion Diagnostics Regional Outlook**

## Market Drivers

### Rising Cancer & Chronic Disease Prevalence

The rising prevalence of cancer and chronic diseases significantly drives the Companion Diagnostics Market by heightening demand for precision medicine tools that identify patients suitable for targeted therapies, optimizing treatment outcomes and minimizing ineffective interventions. In 2022, approximately 20 million new cancer cases occurred worldwide, with projections estimating 35.3 million by 2050 a 76.6% increase particularly sharp in low human development index (HDI) countries at 142%, underscoring the urgent need for biomarker-driven diagnostics. 

 
Chronic conditions exacerbate this, as nearly three-quarters of the global population is expected to live with at least one by 2025, including 76.4% of U.S. adults in 2023 facing issues like hypertension (34.5%), high cholesterol (35.3%), and diabetes (12.1%), which fuel demands for tests in oncology, cardiovascular, and neurological disorders. For instance, HER2 testing in breast cancer, affecting millions annually, pairs with trastuzumab to boost survival rates, while PD-L1 assays like 22C3 guide pembrolizumab use in non-small cell lung cancer, matching therapies to tumor profiles for up to 30-40% response improvements in eligible patients.

### Increasing Drug–Diagnostic Co-Development & Regulatory Approvals

Increasing drug-diagnostic co-development and regulatory approvals propel the Companion Diagnostics Market by synchronizing biomarker tests with targeted therapies, ensuring timely patient access to precision treatments through streamlined parallel pathways. By 2025, co-development has become essential for oncology, immunology, and rare diseases, with structured workflows from biomarker identification to integrated clinical trials aligning timelines for pivotal approvals.
 
The FDA lists over 44 approved companion diagnostics by 2020, surging to more than 35 additional approvals between 2011 and recent years, predominantly for hematological and oncological drugs via platforms like IHC, NGS, and PCR, with most requiring Premarket Approval (PMA) as high-risk devices. For example, in Q1 2025, the FDA approved the Thera screen KRAS RGQ PCR Kit (QIAGEN) as a companion diagnostic for colorectal cancer patients with KRAS G12C mutations eligible for sotorasib, enabling precise stratification amid two such approvals that quarter.

## Future Outlook

The Companion Diagnostics Market size is projected to reach USD 25,300.58 million by 2035, growing at a CAGR of 12.68%, driven by increasing demand for high-performance computing and enhanced security features.

**New opportunities:**

- Expansion beyond oncology into other therapeutic areas
- Growth in bioinformatics, software & services supporting CDx.

By 2035, the Companion Diagnostic Market is expected to be robust, reflecting substantial growth and innovation.

## Segment Insights

### By Test Type: EGFR Mutation Testing (largest market) vs PD-1 Testing (fastest growing)

Based on test type, the Companion Diagnostics Market has been segmented into HER2 Testing, PD-1 Testing, EGFR Mutation Testing, ALK Rearrangement Testing, and Others. EGFR mutation testing holds the largest share, accounting for 31% of the market, primarily due to its extensive use in NSCLC, which represents a significant portion of global lung cancer cases. With lung cancer being one of the leading causes of cancer-related deaths worldwide, the demand for accurate diagnostic tools has surged. 

EGFR testing helps identify patients eligible for targeted therapies like tyrosine kinase inhibitors (TKIs), improving survival rates and treatment outcomes. The growing incidence of NSCLC and other EGFR-related cancers is a key driver for market expansion. PD-1 testing is essential for identifying patients who will benefit from immune checkpoint inhibitors such as pembrolizumab and [nivolumab](https://www.marketresearchfuture.com/reports/nivolumab-market-38933). With immunotherapy becoming a standard treatment for cancers like non-small cell lung cancer (NSCLC), melanoma, and renal cell carcinoma, the demand for PD-1 biomarker testing has surged. This trend is fuelled by the growing clinical evidence supporting PD-1 inhibitors’ effectiveness, making PD-1 testing a critical step in precision oncology.

### By Product & Services: assays, reagents & kits (largest market) vs instruments/systems (fastest-growing)

Based on Product & Services, the Companion Diagnostics Market has been segmented into assays, reagents & kits, instruments/systems, and software & services, with assays holding the largest share of 44% of the market. Assays, reagents, and kits are essential components for performing biomarker-based tests like HER2, EGFR, ALK, and PD-1. The growing need for precision in cancer diagnostics and personalized medicine has increased demand for high-quality reagents and kits that ensure accurate results. 

Their critical role in maintaining test reliability makes them indispensable in clinical workflows, driving consistent market growth. Healthcare providers are increasingly adopting automated instruments to improve efficiency and reduce human error in biomarker testing. These systems enable high-throughput analysis, faster turnaround times, and standardized results, which are critical for precision medicine. Automation also supports scalability in large hospitals and diagnostic labs, driving strong demand for advanced instruments.

### By Technology: polymerase chain reaction (PCR) (largest market) vs next-generation sequencing (NGS) (fastest-Growing)

Based on technology, the Companion Diagnostics Market has been segmented into polymerase chain reaction (PCR), next-generation sequencing (NGS), immunohistochemistry (IHC), fluorescence in-situ hybridization (FISH), and others, with PCR holding the largest share of 36% of the market. PCR technology offers exceptional sensitivity and specificity for detecting genetic mutations and biomarkers, making it a preferred choice for companion diagnostics. Its ability to amplify small amounts of DNA ensures accurate results even from limited samples, which is critical for early cancer detection and personalized treatment planning. 

This reliability drives widespread adoption in clinical settings. Further, cost-effectiveness of PCR compared to advanced technologies like NGS and widely availability and affordability make it suitable for routine testing in hospitals and diagnostic labs, especially in emerging markets. The combination of low cost and high accuracy positions PCR as a dominant technology in companion diagnostics. NGS enables simultaneous analysis of multiple genes and biomarkers in a single test, providing a complete genomic profile of the patient. This capability is crucial for identifying complex mutations and guiding personalized cancer therapies. Its ability to detect rare variants and resistance mutations makes NGS indispensable in precision oncology, driving strong adoption.

### By Indication: cancer (largest market) vs infectious diseases (fastest-Growing)

Based on indication, the Companion Diagnostics Market has been segmented into cancer, neurological disorders, cardiovascular disorders, and infectious diseases, with cancer accounting for 63% of the market share. Cancer remains one of the leading causes of mortality worldwide, with millions of new cases diagnosed annually. The growing prevalence of cancers such as breast, lung, colorectal, and gastric significantly increases the need for accurate biomarker testing. 

For instance, as per the report published by the World Health Organization in 2024, it has been reported that, in 2022, there were an estimated 20 million new cancer cases and 9.7 million deaths. The increasing prevalence of infectious diseases such as HIV, hepatitis, tuberculosis, and emerging viral infections drives demand for accurate diagnostic tools. Companion diagnostics help identify patients who will respond to specific antiviral or antimicrobial therapies, improving treatment outcomes and reducing resistance. This growing disease burden is a major driver for market expansion.

### By End User: Biopharmaceutical and Biotechnology Companies (largest market) vs CROs and CDMOs (fastest-Growing)

Based on end users, the Companion Diagnostics Market has been segmented into Biopharmaceutical and Biotechnology Companies, CROs and CDMOs, and Others, with Biopharmaceutical and Biotechnology Companies holding the largest share at 41% of the market. Biopharmaceutical and biotech companies increasingly rely on companion diagnostics to identify patient populations for targeted therapies. This integration improves clinical trial success rates, reduces costs, and accelerates regulatory approvals. 

By ensuring that drugs are tested on genetically suitable patients, these companies enhance treatment efficacy and safety, driving demand for companion diagnostic solutions. CROs and CDMOs help pharmaceutical companies meet stringent regulatory requirements for companion diagnostics and drug approvals. Their ability to manage complex documentation, quality control, and global compliance drives demand for outsourcing these functions, fuelling growth in this segment. Developing and manufacturing companion diagnostics in-house can be expensive and resource-intensive. CROs and CDMOs offer cost-effective solutions with scalable infrastructure, allowing pharma companies to focus on core R&D while leveraging external expertise for diagnostics development and production.

## Regional Market Share Analysis

**North America: Expanding cancer survivors**

North America leads in the Companion Diagnostics Market Size, accounting for over 0.04% of the global revenue in 2024, the U.S. it is estimated that over 2 million new cancer cases and more than 618,000 deaths, with a growing population of 18.6 million cancer survivors projected to reach 22.4 million by 2035. This epidemiological surge drives demand for personalized medicine, in which CDx play a central role in matching patients with specific targeted therapies effectively expanding the CDx market. Moreover, the enhanced FDA regulatory framework contributes significantly to market growth.

Since 2014, the FDA has issued multiple clear regulatory guidelines (e.g., “In Vitro Companion Diagnostic Devices”) to support early and effective co-development of therapeutics and companion diagnostics. In 2023–2024 alone, the FDA authorized 11 new companion diagnostic claims and expanded nine existing ones associated with oncology IVD devices. This enhanced clarity enables smoother regulatory pathways and faster time-to-market for CDx products, significantly stimulating innovation and investment in the sector.

**Europe: Expanding clinical evidence**

In Europe, the growth of the companion diagnostics (CDx) market in Europe is being driven by a confluence of regulatory advancements, expanding clinical evidence, public health imperatives, and rising disease burdens—all underpinned by authoritative data from EU institutions and the WHO. The introduction and implementation of the In Vitro Diagnostic Regulation (IVDR, EU 2017/746), which became fully applicable in May 2022, represent a significant turning point.

This regulation imposes stricter performance evaluation, clinical evidence, and transparency requirements for high-risk IVDs, including CDx. Under IVDR, notified bodies must now engage in formal consultations with the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) on companion diagnostics, and the EMA has established a dedicated CHMP CDx Expert Group to support these reviews, helping accelerate regulatory alignment between diagnostics and therapies.

**Asia Pacific: Rapidly clinical evidence**

Asia Pacific, the growth of the Companion Diagnostics (CDx) market in the Asia Pacific region is propelled by a convergence of rapidly rising cancer incidence, maturing regulatory frameworks, expanding government screening programs, and increasing reimbursement support. According to GLOBOCAN 2022, Asia recorded nearly 9.83 million new cancer cases and 5.46 million deaths, accounting for roughly 50% of global cancer incidence and 58% of cancer deaths.

Within individual markets, the burden is stark: China reported approximately 4.82 million cases in 2022, India logged 1.41 million cases with almost 917,000 deaths, and Japan saw over 1 million cases that year—all underscoring an urgent demand for precision medicine tools like CDx that enable targeted therapy and improved outcomeslutide.

## Competitive Benchmarking

Many global, regional, and local vendors characterize the Companion Diagnostics Market. The market is highly competitive, with all the players competing to gain market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront market growth.
 
The vendors compete based on cost, product quality, reliability, and government regulations. Vendors must provide cost-efficient, high-quality products to survive and succeed in an intensely competitive market.The major players in the market Include Qiagen, Bio-Techne, BioMérieux, Thermo Fisher Scientific Inc., Illumina, Inc., Agilent Technologies, Inc., F. Hoffmann-la Roche Ltd, strategic market developments and decisions to improve operational effectiveness.

## Recent News & Developments

**June 2025**: Alma's strategic focus lies in delivering smart, user-friendly systems that combine clinical efficacy with operational efficiency. The company continues to expand its global reach through innovation-led R&D, regulatory compliance, and practitioner education. Alma’s products hold certifications from leading regulatory bodies, including the U.S. FDA, CE Mark, TGA, Health Canada, and other regional authorities. In line with its digital transformation goals, Alma incorporates smart interfaces, data-driven treatment protocols, and IoT-ready infrastructure into selected platforms to enhance treatment consistency, safety, and practice efficiency.

**June 2025**: Bausch + Lomb's primary objective is to expand the proportion of externally generated ideas in its pipeline strategy, with a focus on internal research and strategic alliances with the outside world. Its focus on R&D expenditure is also on growing its product portfolio. By acquiring small companies and collaborating with bigger companies, it also seeks to increase its global market share. Its main line of business is the production of pharmaceuticals and eye care products. In addition, the company seeks to remain a leader in technology and continue offering unique, superior products through an international distribution network.

**September 2025**: Venus Concept places strategic emphasis on continuous innovation, technology integration, and practitioner-focused support. The company channels significant investment into research and development to engineer next-generation, non-invasive and minimally invasive solutions that address high-demand treatment areas such as body contouring, cellulite reduction, skin tightening, and hair restoration. Its proprietary platforms—integrating technologies like diode laser lipolysis, multi-polar radiofrequency, pulsed electromagnetic fields, and EMS—are designed to deliver clinically validated outcomes with enhanced patient comfort and minimal downtime.

## Report Scope

| Market Size 2024 | 6,828.25 (USD Million) |
| --- | --- |
| Market Size 2025 | 7694.07 (USD Million) |
| Market Size 2035 | 25,300.58 (USD Million) |
| Compound Annual Growth Rate (CAGR) | 12.68% (2025 - 2035) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2023 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Qiagen, Bio-Techne, BioMérieux, Thermo Fisher Scientific Inc., Illumina, Inc., Agilent Technologies, Inc., F. Hoffmann-la Roche Ltd. |
| Segments Covered | By Test Type, By Product & Services, By Technology, By Indication, By End User |
| Key Market Opportunities | Expansion beyond oncology into other therapeutic areas. Growth in bioinformatics, software & services supporting CDx. |
| Key Market Dynamics | High Cost & Capital Investment for CDx Development and Testing. Regulatory Complexity and Varied Approval Pathways. Limited Reimbursement, Uneven Access & Awareness. |
| Region Covered | North America, Europe, Asia Pacific. |

## Frequently Asked Questions

**Q: How much is the Companion Diagnostics Market?**
A: USD 25,300.58 Million (2035)

**Q: What is the growth rate of the Companion Diagnostics Market?**
A: 12.68%

**Q: Which region held the largest market share in the Companion Diagnostics Market?**
A: North America

**Q: Who are the key players in the Companion Diagnostics Market?**
A: Qiagen, Bio-Techne, BioMérieux, Thermo Fisher Scientific Inc., Illumina, Inc., Agilent Technologies, Inc., F. Hoffmann-la Roche Ltd.

**Q: Which Indication had the largest market share in the Companion Diagnostics Market?**
A: Cancer


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/companion-diagnostic-market-3077*